argenx SE

AdCom AI-extracted

VYVGART

ocular myasthenia gravis (oMG)

Date

TBD

Advisory committee · Date TBD estimated

What's at stake An FDA advisory committee reviews VYVGART for ocular myasthenia gravis (oMG) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.

Primary source · SEC 6-K verified 11h ago

“FDA review of the VYVGART sBLA submission for the treatment of AChR-Ab seronegative gMG;”

Add to calendar Post on X Reddit

Provenance